EASL (Amsterdam 2017). Exciting to see the series of LOWR abstracts at EASL highlighting the Hepatitis Delta studies with Lonafarnib. SPRI clinical has enjoyed the great partnership with the sites in advancing the understanding of Hepatitis Delta.
Wow! 24 thousand participants treated in Mass Drug Administration (Haiti, India, Indonesia, & PNG) in 5 months. Great collaboration with the DOLF (Death to Oncho and Lymphatic Filiaris) team from Washington University and the Bill and Melinda Gates Foundation!
After two years across multiple countries (Bulgaria, Czech Republic, Romania, Georgia, and the US) the HRV study came to an end and unfortunately didn’t produce the efficacy required to take development to the next step.